Malignant Melanoma Treatment Market Report 2026

The malignant melanoma treatment market size has grown rapidly in recent years. It will grow from $7.98 billion in 2025 to $8.78 billion in 2026 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to rising incidence of skin cancer globally, increased exposure to ultraviolet radiation, early development of chemotherapy-based melanoma treatments, growing awareness of melanoma symptoms, initial success of surgical melanoma management.

The malignant melanoma treatment market size is expected to see rapid growth in the next few years. It will grow to $13.37 billion in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to increasing approval of advanced immunotherapies, growing emphasis on personalized cancer treatment, rising investment in oncology research and development, expansion of melanoma screening programs, increasing healthcare access in emerging markets. Major trends in the forecast period include rising adoption of immunotherapy-based treatments, growing use of combination treatment regimens, increasing focus on early-stage melanoma intervention, expansion of clinical trials for novel melanoma therapies, higher demand for specialized oncology care centers.

The rising incidence of melanoma is anticipated to drive the growth of the malignant melanoma treatment market in the coming years. Melanoma is a type of skin cancer that originates in melanocytes, the skin cells responsible for producing pigment. Treatment for melanoma typically includes surgical removal of the tumor, with additional therapies such as immunotherapy or targeted therapy recommended depending on the stage and severity of the cancer. For example, in February 2023, the Melanoma Research Foundation, a US-based organization, reported that the total number of melanoma cases in the United States in 2023 was 187,000, which increased by 7.3% to reach 200,651 in 2024. Consequently, the rising incidence of melanoma is fueling the growth of the malignant melanoma treatment market.

Major companies operating in the malignant melanoma treatment market are concentrating on developing innovative solutions, such as autologous tumor-infiltrating lymphocyte (TIL) therapies, to address the increasing demand for effective post-checkpoint immunotherapies and personalized cell-based options for patients who progress after PD-1 inhibitors and targeted therapies. Autologous tumor-infiltrating lymphocyte (TIL) therapy is a form of immunotherapy in which a patient’s own immune cells that have infiltrated their tumor are collected, expanded in the laboratory, and reinfused to enhance the body’s ability to target and destroy cancer cells. For example, in February 2024, Iovance Biotherapeutics, a US-based biopharmaceutical company, introduced AMTAGVI (lifileucel), an autologous TIL therapy for adults with unresectable or metastatic melanoma who have progressed following prior PD-1 therapy (and targeted therapy if BRAF V600-mutant). AMTAGVI (lifileucel) consists of expanded tumor-infiltrating lymphocytes derived from the patient’s own tumor and reinfused after conditioning; it works by amplifying tumor-reactive T cells to mediate tumor cell destruction. The therapy’s distinctive characteristics include personalized manufacturing, a single-administration treatment approach, and the ability to recognize multiple tumor antigens.

In October 2023, Bristol-Myers Squibb Company, a US-based biopharmaceutical company, acquired Mirati Therapeutics, Inc. for an undisclosed sum. Through this acquisition, Bristol-Myers Squibb Company sought to strengthen and diversify its oncology portfolio by incorporating an approved KRAS G12C inhibitor along with complementary clinical-stage assets to accelerate growth and combination strategies. Mirati Therapeutics, Inc. is a US-based biotechnology company focused on discovering and developing targeted oncology therapies, notably KRAZATI (adagrasib), a KRAS G12C inhibitor, and a pipeline of KRAS- and PRMT5-targeting candidates.

Major companies operating in the malignant melanoma treatment market are Johnson & Johnson Private Limited, Pfizer Inc., Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Mylan N.V., Chugai Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Ono Pharmaceutical Co. Ltd., Exelixis Inc., Array BioPharma Inc., Pierre Fabre Group, Clinigen Group, Iovance Biotherapeutics Inc., X4 Pharmaceuticals Inc., Mirati Therapeutics Inc., Moleculin Biotech Inc., Polynoma LLC, Enzon Pharmaceuticals Inc., Northwest Biotherapeutics Inc.

North America was the largest region in the malignant melanoma treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant melanoma treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the malignant melanoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately affected the malignant melanoma treatment market by increasing costs for imported oncology drugs, biologics, and specialized medical equipment. These impacts are most visible in immunotherapy and targeted therapy segments, particularly in regions dependent on cross-border pharmaceutical trade such as asia-pacific and parts of europe. Higher tariffs can elevate treatment costs and delay access to advanced therapies. However, tariffs have also encouraged local drug manufacturing and regional clinical research, supporting long-term market resilience.

The malignant melanoma treatment market research report is one of a series of new reports that provides malignant melanoma treatment market statistics, including malignant melanoma treatment industry global market size, regional shares, competitors with a malignant melanoma treatment market share, detailed malignant melanoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the malignant melanoma treatment industry. This malignant melanoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Malignant melanoma treatment involves medical interventions and therapies designed to manage and potentially cure malignant melanoma, a form of skin cancer that arises from melanocytes, the cells responsible for producing the skin pigment melanin. Treating malignant melanoma provides several benefits essential for the health and potential recovery of individuals diagnosed with this aggressive type of skin cancer.

The primary treatments for malignant melanoma include immunotherapy, radiation therapy, chemotherapy, and others. Immunotherapy is a medical approach that utilizes the body’s own immune system to combat diseases, including certain cancers. It is used in the treatment of lentigo malignant melanoma, acral lentiginous melanoma, nodular melanoma, and superficial spreading melanoma, and is administered by various end-users such as hospitals, specialty clinics, and others.

The malignant melanoma treatment market consists of revenues earned by entities by providing services such as diagnosis and staging services, surgical services, medical treatments, genetic counseling, aesthetic services, and cosmetic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The malignant melanoma treatment market also includes sales of aldesleukin, binimetinib, braftovi (encorafenib), cobimetinib fumarate, cotellic (cobimetinib fumarate), dabrafenib mesylate, dacarbazine, and encorafenib. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.